Magellan Biosciences has received the US Food And Drug Administration (FDA) approval for its new TREK Diagnostic Systems-brand Sensititre AIM Automated Inoculation Delivery System for use with all Sensititre dried plates.
The Sensititre AIM System allows clinicians to dose microtitre plates, eliminating both skipped wells and costly repeat tests to improve laboratory workflow.
Magellan claims the system’s design is ideal for use directly on the benchtop or under a microbiology safety cabinet.
The system also features icon-driven touch screen which helps to select dosing volumes and patterns to operate.
Magellan president and CEO Hiroshi Uchida said the goal of the new Sensititre AIM System and all of their IVD susceptibility products is to make it easier for clinicians todetermine the right combination of antimicrobics to fight infection and the emerging problem of drug resistance.
The AIM System has also received CE/IVD-mark approval.